# Phase 2 Clinical Trial of CartiLife® in the United States

> **NCT04744402** · PHASE2 · RECRUITING · sponsor: **Biosolution Co., Ltd.** · enrollment: 25 (estimated)

## Conditions studied

- Articular Cartilage Defect
- Articular Cartilage Degeneration

## Interventions

- **DRUG:** Autologous Chondrocyte Implantation (CartiLife®)

## Key facts

- **NCT ID:** NCT04744402
- **Lead sponsor:** Biosolution Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-28
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04744402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04744402, "Phase 2 Clinical Trial of CartiLife® in the United States". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04744402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*